These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10100429)

  • 21. Reversible dementia with parkinsonian features associated with budesonide use.
    Prodan CI; Monnot M; Ross ED; Coleman AE
    Neurology; 2006 Aug; 67(4):723. PubMed ID: 16924038
    [No Abstract]   [Full Text] [Related]  

  • 22. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs.
    Gill SS; Mamdani M; Naglie G; Streiner DL; Bronskill SE; Kopp A; Shulman KI; Lee PE; Rochon PA
    Arch Intern Med; 2005 Apr; 165(7):808-13. PubMed ID: 15824303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study.
    Prasher VP; Adams C; Holder R;
    Int J Geriatr Psychiatry; 2003 Jun; 18(6):549-51. PubMed ID: 12789681
    [No Abstract]   [Full Text] [Related]  

  • 25. [Long-term treatment of Alzheimer's disease: followup of a cohort of 255 patients treated with lacrine for four years].
    Michel BF; Estadieu MC; Gueriot C; Berthezène P; Allain H; Bongrand MC; Bonnefoy B; Bourrin JC; Chaix L; Graa K; Lejeune A; Messana M; Pras P; Ribiere J; Rihet P; Timon-David P; Tintignac A; Vincent S; Verdier JM; Gastaut JL
    Rev Neurol (Paris); 2001 Nov; 157(11 Pt 1):1365-75. PubMed ID: 11924005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donepezil: new preparation. Moderate efficacy in Alzheimer's disease.
    Prescrire Int; 1998 Oct; 7(37):146-7. PubMed ID: 10915420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upper gastrointestinal bleeding in elderly adults with dementia receiving cholinesterase inhibitors: a population-based cohort study.
    Thavorn K; Gomes T; Camacho X; Yao Z; Juurlink D; Mamdani M
    J Am Geriatr Soc; 2014 Feb; 62(2):382-4. PubMed ID: 24521369
    [No Abstract]   [Full Text] [Related]  

  • 28. AAFP and ACP release guideline on dementia treatment.
    Graham L
    Am Fam Physician; 2008 Apr; 77(8):1173-5. PubMed ID: 18481566
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse events in patients receiving cholinesterase inhibitors due to dissimilar follow-up periods.
    Chan M
    Arch Intern Med; 2009 Oct; 169(18):1724; author reply 1724-5. PubMed ID: 19822833
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice.
    Saxena G; Singh SP; Agrawal R; Nath C
    Eur J Pharmacol; 2008 Mar; 581(3):283-9. PubMed ID: 18234183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of centrally acting cholinesterase inhibitor exposures in adults.
    McCain KR; Sawyer TS; Spiller HA
    Ann Pharmacother; 2007 Oct; 41(10):1632-7. PubMed ID: 17848422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
    Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinesterase inhibitors and use of psychotropic medications in a sample of patients with dementia.
    Shamsi M; Rice K; Rao VB
    J Am Geriatr Soc; 2007 Dec; 55(12):2099-100. PubMed ID: 18081685
    [No Abstract]   [Full Text] [Related]  

  • 34. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
    Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
    Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
    Hartmann S; Möbius HJ
    Int Clin Psychopharmacol; 2003 Mar; 18(2):81-5. PubMed ID: 12598818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
    Poirier J
    Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and management of dementia in general practice.
    Pond D; Brodaty H
    Aust Fam Physician; 2004 Oct; 33(10):789-93. PubMed ID: 15532152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
    Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
    Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Good evidence for benefits of cholinesterase inhibitors in Parkinson dementia is still missing].
    Larsson A
    Lakartidningen; 2006 May 10-16; 103(19):1537; discussion 1537-8. PubMed ID: 16805251
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.